Table 1. Subject Descriptive Information.

	SZs (N=17)	NCs (N=17)	p of Group diff.
	Mean (SD)	Mean (SD)
Demographic information
Age	37.8 (9.6)	37.8 (8.1)	0.977
Gender	13 M, 4 F	12 M, 5 F	1.000
Race	12 W, 5 NW	7 W, 10 NW	0.166
Subject ed. (yrs.)	12.7 (2.7)	14.8 (2.3)	0.030
Father's ed. (yrs.)	14.5 (3.8)	14.2 (2.0)	0.838
Neuropsychological performance
WTAR—scaled	103.8 (16.3)	107.6 (12.7)	0.474
WASI—full	104.9 (15.3)	115.4 (12.2)	0.050
RBANS—total	86.6 (16.5)	101.8 (11.8)	0.010
Symptom ratings
BPRS	28.9 (8.3)
SANS	30.2 (22.7)
CDS	0.7 (1.0)
Antipsychotic drug information
Haloperidol	1 Patient
Olanzapine	2 Patients
Risperidone	7 Patients
Ziprasidone	1 Patient
Clozapine only	3 Patients
Clozapine+	3 Patients

Abbreviations: SZs, schizophrenia patients; NCs, normal controls; diff., difference; M, male; F, female; W, white; NW, non-white; ed., education; yrs., years; WTAR, Wechsler Test of Adult Reading (Wechsler, 2001); WASI, Wechsler Abbreviated Scale of Intelligence (Wechsler, 1999); RBANS, Repeatable Battery for the Assessment of Neuropsychological Status (Randolph et al, 1998; Wilk et al, 2005); BPRS, Brief Psychiatric Rating Scale; SANS, Scale for the Assessment of Negative Symptoms; CDS, Calgary Depression Scale.

Bold values indicate significant group difference.